The development of non-hormonal contraceptives for males
By Ambika Robinson
In a world where women have pills, emergency pills, implants, patches, injections and more it is no surprise that it is usually women who end up on some form of contraception. However, while this array of options is helpful, they all have their side effects, often due to the hormonal effect these treatments have. Hormonal treatments for both men and women often come with side effects affecting the whole body. For example, migraines, nausea, impact on hair growth and mood swings.
When it comes to male contraception, condoms and vasectomies are the most obvious. Male contraception may have been seen as a more difficult task since, after puberty, men produce around 1000 sperm per second. An effective contraception would have to ensure that millions of sperm are all either unable to reach the egg, or stop sperm production altogether, to prevent fertilisation.
One hormonal male contraception technique uses an external testosterone administration which suppresses LH and FSH levels and results in decreased sperm concentrations after 2-3 months. This was found to be safe and fully reversible however did not reduce sperm functionality to zero. Progestins are another hormonal method to inhibit spermatogenesis. Progestins are synthetic progestogens, which suppress the production of key hormones necessary for sperm production.
While both these therapies have proven effective, and even more effective when combined, there is some caution surrounding hormonal therapies. Hormonal male contraceptives tend to be approached with caution due to concerns about their potential impact on long-term fertility, libido, and overall sperm production. The focus has therefore shifted towards non-hormonal options, not only due to the potential side effects but also, to reduce any scepticism which might mean that men do not want to use contraceptives.
Hormonal therapies can impact long-term fertility and libido
One of the non-hormonal male contraception options is TDI-11861, aimed to damage the speed and agility of the sperm cells which meant they were not strong enough to reach the egg cell for fertilisation. The drug would be taken around an hour before sex, and its effects lasted for 3 hours but by 24 hours its effects would have worn off, the sperm and the male’s fertility are fully restored.
This drug is an sAC inhibitor, or a soluble adenylyl cyclase, increased levels of sAC triggers the signalling pathway to activate sperm motility and capacitation. Sperm cells are stored dormant in the cauda epididymis. Upon ejaculation, the sperm cells mix with semen and so the sperm cells are exposed to higher concentrations of bicarbonate which results in activation of bicarbonate-regulated soluble adenylyl cyclase which is the initial step of the motility and capacitation pathway mentioned previously.
The second drug, another exciting name- CDD-2807, targets STK33 (serine/threonine kinase 33), a kinase found in the testes which is key for sperm motility and morphology. Men and mice who lack this kinase are infertile, and so the drug works to inhibit this kinase. CDD-2807 was found to effectively inhibit this kinase, therefore inducing sterility without any toxicity, or side effects to the testes or brain and the effects are reversible.
A study conducted in 2023 found that in a group of men among the reproductive age 18-45, 72% of the participants were willing to use a male contraception. While the percentage of men who are willing to use contraceptives seems to vary between studies, it is promising that it is usually over 50%. To increase these percentages, it is important there clearer communication of the contraceptive options available to men and how and when they can access them.
Image via Wikimedia Commons

